

Why 3 Biotechs Upgraded their EDC to Veeva Vault

Support for complex trials without reliance on custom functions, no downtime during amendments, and faster study build and close out. Emerging biotechs are updating their EDC to an innovative system that efficiently supports clinical trials. Here's why organizations like yours made the switch to Veeva.



Supporting Complexity, at a Global Scale

"We are running platform trials with global scale across multiple countries and with multiple arms. Veeva was the best, and other EDCs fell short."

– Michael Zimmerman, Platform Life Sciences

- Conducted a large outpatient COVID trial: 14,000 patients, 12 interventions
- Legacy data infrastructure was slowing them down
- Looked to Veeva to power complex, global trials



Eliminating Costly Custom Functions & Downtime

"Custom functions can be challenging. We don't have the skillset in-house, and are dependent on a technology partner. When I saw that Veeva could handle our trials without custom functions, that was exciting... that basically sold me on Veeva."

– Deepak Mahadevaiah, Agenus

- Eliminated custom functions with Veeva
- No more downtime during amendments
- Innovative tools to manage oncology lab data



A Foundation for the Future: Working Smarter, Not Harder

"This solution created simplicity at every level and for all stakeholders, the site, data management, the operational team, and for the drug supply team."

– Catherine Munera, Ph.D., Cara Therapeutics

- Saw 50% faster build times than previous EDC
- Improved CRF consistency and standardized trial data when working with CROs
- Leveraged productized IRT integration to support patient and drug logistics

Ready to save time with Veeva Vault EDC?

[Learn More](#)